The use of aromatase inhibitors in in vitro fertilization
review
OA: closed
public-domain-us
AI-generated summary
This paper reviews the controversial use of aromatase inhibitors in IVF for patients with endometriosis, poor response, or hyperstimulation risk, noting that efficacy requires validation through randomized trials.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The use of aromatase inhibitors (AIs) in IVF patients remains controversial. AIs can be considered for ovulation induction for IVF in women who are normal and poor responders, are at risk of ovarian hyperstimulation syndrome or thrombosis, who have endometriosis, and/or are undergoing fertility preservation procedures as a result of estrogen-dependent cancers, primarily breast and endometrial cancers. Although the biologic plausibility of the capacity of AIs in IVF patients is promising, results should be interpreted with caution, because the efficacy of AIs needs to be proven in randomized trials.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (1)
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-09-27T09:11:36.575535+00:00
- pubmed
- last seen: 2026-05-13T22:15:58.344756+00:00
- unpaywall
- last seen: 2026-09-18T06:25:56.777850+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine